SOURCE: OmniComm Systems, Inc.

April 28, 2005 09:54 ET

OmniComm Expands to Asia With CRO Partner APEX International Clinical Reasearch Co., Ltd.

FT. LAUDERDALE, FL -- (MARKET WIRE) -- April 28, 2005 -- OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that CRO APEX International Clinical Research Co., Ltd. has selected OmniComm's TrialMaster® system as their in-house EDC solution. OmniComm will provide a custom, private-label version of their popular TrialMaster EDC system to APEX.

APEX, a well-known, fast-growing contract research organization based in Asia, selected OmniComm's TrialMaster suite of EDC products after conducting an extensive evaluation of existing EDC products. "We concluded that TrialMaster offered the features, flexibility and price required by our company for deployment as our in-house standard," stated Albert Liou, CEO and Chairman of APEX.

"We are honored to be associated with an outstanding, respected company such as APEX," stated Cornelis Wit, CEO and President of OmniComm. "OmniComm has several global clients, and it is of utmost importance for us to be able to offer outstanding services in the Far East. We look forward to supporting APEX with their clinical data requirements as well as providing our existing clients with a top-quality Asian-based CRO."

About Apex International Clinical Research Co., Ltd.

APEX ( is a leading CRO in the Asia-Pacific region that offers cost-effective yet client-tailored services. Their service spectrum encompasses medical and regulatory consultations, clinical monitoring, project management, statistical analysis, data management and site management. Their mission is to become the number one choice for clinical research partners in Asia where they have established presence in 10 countries including China, Taiwan, Hong Kong, Korea, Singapore, The Philippines, Malaysia, Thailand, Australia and New Zealand.

About OmniComm Systems, Inc.

OmniComm Systems, Inc. ( is one of the fastest growing companies in the EDC market place, targeting its product TrialMaster® to the pharmaceutical, medical device and biotechnology companies as well as CROs. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employees' commitment to on-time, quality and within-budget performance.

The TrialMaster ( system, the core product of OmniComm, provides trial sponsors with a 21 CRF Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • For more info, please contact:
    Rusty Beardsley
    Sr. VP Marketing and Sales
    OmniComm Systems, Inc.